Walgreens Boots Alliance, Inc. (WBA) Stock Competitors & Peer Comparison

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, ONC has a market cap of 29.9B. Regarding current trading prices, WBA is priced at $11.98, while ONC trades at $279.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas ONC's P/E ratio is 63.33. In terms of profitability, WBA's ROE is -0.42%, compared to ONC's ROE of +0.12%. Regarding short-term risk, WBA is less volatile compared to ONC. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check ONC's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, WBA is priced at $11.98, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas HROWL's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, WBA is less volatile compared to HROWL. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check HROWL's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, WBA is priced at $11.98, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas HROWM's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, WBA is less volatile compared to HROWM. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check HROWM's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, AVLN has a market cap of 1.1B. Regarding current trading prices, WBA is priced at $11.98, while AVLN trades at $26.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas AVLN's P/E ratio is -13.23. In terms of profitability, WBA's ROE is -0.42%, compared to AVLN's ROE of N/A. Regarding short-term risk, WBA is less volatile compared to AVLN. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check AVLN's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, CGEM has a market cap of 887.5M. Regarding current trading prices, WBA is priced at $11.98, while CGEM trades at $14.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas CGEM's P/E ratio is -4.28. In terms of profitability, WBA's ROE is -0.42%, compared to CGEM's ROE of -0.51%. Regarding short-term risk, WBA is less volatile compared to CGEM. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check CGEM's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, LFMD has a market cap of 235.5M. Regarding current trading prices, WBA is priced at $11.98, while LFMD trades at $4.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas LFMD's P/E ratio is -11.07. In terms of profitability, WBA's ROE is -0.42%, compared to LFMD's ROE of -1.72%. Regarding short-term risk, WBA is less volatile compared to LFMD. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check LFMD's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, HITI has a market cap of 209.2M. Regarding current trading prices, WBA is priced at $11.98, while HITI trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas HITI's P/E ratio is -5.67. In terms of profitability, WBA's ROE is -0.42%, compared to HITI's ROE of -0.41%. Regarding short-term risk, WBA is less volatile compared to HITI. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check HITI's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, LFMDP has a market cap of 161.3M. Regarding current trading prices, WBA is priced at $11.98, while LFMDP trades at $23.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas LFMDP's P/E ratio is -10.48. In terms of profitability, WBA's ROE is -0.42%, compared to LFMDP's ROE of -1.72%. Regarding short-term risk, WBA is less volatile compared to LFMDP. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check LFMDP's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, WBA is priced at $11.98, while LFLY trades at $37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas LFLY's P/E ratio is -0.04. In terms of profitability, WBA's ROE is -0.42%, compared to LFLY's ROE of +0.17%. Regarding short-term risk, WBA is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check LFLY's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, YI has a market cap of 43.2M. Regarding current trading prices, WBA is priced at $11.98, while YI trades at $4.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas YI's P/E ratio is -4.43. In terms of profitability, WBA's ROE is -0.42%, compared to YI's ROE of +0.08%. Regarding short-term risk, WBA is less volatile compared to YI. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check YI's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, RKTO has a market cap of 41.4M. Regarding current trading prices, WBA is priced at $11.98, while RKTO trades at $1.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas RKTO's P/E ratio is -2.18. In terms of profitability, WBA's ROE is -0.42%, compared to RKTO's ROE of -1.65%. Regarding short-term risk, WBA is less volatile compared to RKTO. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check RKTO's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, PETS has a market cap of 38.7M. Regarding current trading prices, WBA is priced at $11.98, while PETS trades at $1.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas PETS's P/E ratio is -0.66. In terms of profitability, WBA's ROE is -0.42%, compared to PETS's ROE of -1.47%. Regarding short-term risk, WBA is less volatile compared to PETS. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check PETS's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, WBA is priced at $11.98, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas RAD's P/E ratio is -0.05. In terms of profitability, WBA's ROE is -0.42%, compared to RAD's ROE of +2.76%. Regarding short-term risk, WBA is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check RAD's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, SDEV has a market cap of 32.8M. Regarding current trading prices, WBA is priced at $11.98, while SDEV trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas SDEV's P/E ratio is -0.21. In terms of profitability, WBA's ROE is -0.42%, compared to SDEV's ROE of +17.15%. Regarding short-term risk, WBA is less volatile compared to SDEV. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check SDEV's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, RNTX has a market cap of 29.1M. Regarding current trading prices, WBA is priced at $11.98, while RNTX trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas RNTX's P/E ratio is -0.55. In terms of profitability, WBA's ROE is -0.42%, compared to RNTX's ROE of -2.58%. Regarding short-term risk, WBA is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check RNTX's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, KYNB has a market cap of 27.6M. Regarding current trading prices, WBA is priced at $11.98, while KYNB trades at $6.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas KYNB's P/E ratio is -0.49. In terms of profitability, WBA's ROE is -0.42%, compared to KYNB's ROE of -2.34%. Regarding short-term risk, WBA is less volatile compared to KYNB. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check KYNB's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, NEUP has a market cap of 25.9M. Regarding current trading prices, WBA is priced at $11.98, while NEUP trades at $4.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas NEUP's P/E ratio is -0.61. In terms of profitability, WBA's ROE is -0.42%, compared to NEUP's ROE of -1.10%. Regarding short-term risk, WBA is less volatile compared to NEUP. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check NEUP's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, WBA is priced at $11.98, while MEDS trades at $7.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas MEDS's P/E ratio is -0.31. In terms of profitability, WBA's ROE is -0.42%, compared to MEDS's ROE of -1.21%. Regarding short-term risk, WBA is less volatile compared to MEDS. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check MEDS's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, POM has a market cap of 12.2M. Regarding current trading prices, WBA is priced at $11.98, while POM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas POM's P/E ratio is -0.30. In terms of profitability, WBA's ROE is -0.42%, compared to POM's ROE of +0.07%. Regarding short-term risk, WBA is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check POM's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, WBA is priced at $11.98, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas CJJD's P/E ratio is -0.46. In terms of profitability, WBA's ROE is -0.42%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, WBA is less volatile compared to CJJD. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check CJJD's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, WBA is priced at $11.98, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas SSY's P/E ratio is -2.86. In terms of profitability, WBA's ROE is -0.42%, compared to SSY's ROE of -0.15%. Regarding short-term risk, WBA is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check SSY's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, MSLE has a market cap of 7.7M. Regarding current trading prices, WBA is priced at $11.98, while MSLE trades at $6.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas MSLE's P/E ratio is -3.36. In terms of profitability, WBA's ROE is -0.42%, compared to MSLE's ROE of -0.67%. Regarding short-term risk, WBA is less volatile compared to MSLE. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check MSLE's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, AIXC has a market cap of 6.7M. Regarding current trading prices, WBA is priced at $11.98, while AIXC trades at $1.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas AIXC's P/E ratio is -0.18. In terms of profitability, WBA's ROE is -0.42%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, WBA is less volatile compared to AIXC. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check AIXC's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, HKPD has a market cap of 5.5M. Regarding current trading prices, WBA is priced at $11.98, while HKPD trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas HKPD's P/E ratio is -8.42. In terms of profitability, WBA's ROE is -0.42%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, WBA is less volatile compared to HKPD. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check HKPD's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, WBA is priced at $11.98, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas MDVL's P/E ratio is -0.05. In terms of profitability, WBA's ROE is -0.42%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, WBA is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check MDVL's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, WBA is priced at $11.98, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas ATNFW's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, WBA is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check ATNFW's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, WBA is priced at $11.98, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas BGMSP's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, WBA is less volatile compared to BGMSP. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check BGMSP's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, BGMS has a market cap of 2.3M. Regarding current trading prices, WBA is priced at $11.98, while BGMS trades at $1.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas BGMS's P/E ratio is 0.21. In terms of profitability, WBA's ROE is -0.42%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, WBA is less volatile compared to BGMS. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check BGMS's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, WBA is priced at $11.98, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas AZNH's P/E ratio is 38.35. In terms of profitability, WBA's ROE is -0.42%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, WBA is less volatile compared to AZNH. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check AZNH's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, WBA is priced at $11.98, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, WBA's ROE is -0.42%, compared to LFLYW's ROE of +0.17%. Regarding short-term risk, WBA and LFLYW have similar daily volatility (0.00).Check LFLYW's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, WBA is priced at $11.98, while BIMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas BIMI's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, WBA and BIMI have similar daily volatility (0.00).Check BIMI's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, WBA is priced at $11.98, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas IPXL's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, WBA is less volatile compared to IPXL. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check IPXL's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, OREX has a market cap of 0. Regarding current trading prices, WBA is priced at $11.98, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas OREX's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to OREX's ROE of -0.54%. Regarding short-term risk, WBA is less volatile compared to OREX. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check OREX's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, CPD has a market cap of 0. Regarding current trading prices, WBA is priced at $11.98, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas CPD's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to CPD's ROE of N/A. Regarding short-term risk, WBA is less volatile compared to CPD. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check CPD's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, WBA is priced at $11.98, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas ESRX's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, WBA and ESRX have similar daily volatility (0.00).Check ESRX's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, WBA is priced at $11.98, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas SHPG's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, WBA and SHPG have similar daily volatility (0.00).Check SHPG's competition here

WBA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WBA stands at 10.4B. In comparison, POZN has a market cap of 0. Regarding current trading prices, WBA is priced at $11.98, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WBA currently has a P/E ratio of -1.64, whereas POZN's P/E ratio is N/A. In terms of profitability, WBA's ROE is -0.42%, compared to POZN's ROE of +0.61%. Regarding short-term risk, WBA is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for WBA.Check POZN's competition here